591,253 Shares in ABIVAX Société Anonyme (NASDAQ:ABVX) Acquired by Allostery Investments LP

Allostery Investments LP bought a new stake in ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 591,253 shares of the company's stock, valued at approximately $4,328,000. ABIVAX Société Anonyme accounts for about 4.5% of Allostery Investments LP's portfolio, making the stock its 5th largest holding. Allostery Investments LP owned 0.93% of ABIVAX Société Anonyme as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of ABVX. abrdn plc grew its position in ABIVAX Société Anonyme by 34.1% in the 4th quarter. abrdn plc now owns 424,181 shares of the company's stock worth $3,105,000 after purchasing an additional 107,750 shares during the last quarter. JPMorgan Chase & Co. bought a new position in shares of ABIVAX Société Anonyme in the fourth quarter worth $5,336,000. GAMMA Investing LLC acquired a new position in shares of ABIVAX Société Anonyme during the fourth quarter valued at $29,000. Guggenheim Capital LLC acquired a new stake in ABIVAX Société Anonyme in the fourth quarter worth about $92,000. Finally, Franklin Resources Inc. increased its stake in ABIVAX Société Anonyme by 10.7% during the 4th quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company's stock valued at $10,732,000 after buying an additional 141,710 shares during the period. Institutional investors and hedge funds own 47.91% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on ABVX. Morgan Stanley reissued an "equal weight" rating and set a $12.00 target price on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th. JMP Securities reaffirmed a "market outperform" rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a research report on Wednesday, April 30th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, ABIVAX Société Anonyme has an average rating of "Buy" and an average price target of $34.00.

ABIVAX Société Anonyme Trading Up 1.1 %

Shares of ABVX stock traded up $0.08 on Wednesday, reaching $6.83. 39,424 shares of the stock were exchanged, compared to its average volume of 132,492. The stock has a 50 day moving average price of $6.57 and a 200 day moving average price of $7.48. ABIVAX Société Anonyme has a one year low of $4.77 and a one year high of $15.06.

ABIVAX Société Anonyme Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.